Iloperidone for schizophrenia.
BACKGROUND
No existing antipsychotic adequately controls all symptoms associated with schizophrenia. Also, no antipsychotic adequately benefits most patients with this disorder. Finally, the safety and tolerability of each antipsychotic frequently dictate the choice of agent.


METHODS
The mechanism of action of iloperidone, its efficacy and its safety and tolerability when used to treat patients with schizophrenia.


RESULTS
An appreciation of the potential advantages and disadvantages of iloperidone when used for the treatment of schizophrenia.


CONCLUSIONS
Iloperidone is a recent addition to the current group of second-generation antipsychotics. While it may share many qualities with other agents in this class, its unique neuroreceptor signature and adverse-effect profile may prove beneficial in clinical practice.
Rado
Jeffrey
J
Psychiatric Clinical Research Center, Rush University Medical Center, Chicago, IL 60612, USA. Jeffrey_Rado@rush.edu
Janicak
Philip G
PG
D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018492:Dopamine Antagonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017277:Drug Approval; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010597:Pharmacogenetics; D010880:Piperidines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D007555:Isoxazoles; D010880:Piperidines; D012702:Serotonin Antagonists; C081732:iloperidone